Literature DB >> 22395645

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

Catherine M Kelly, Kathleen I Pritchard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22395645     DOI： 10.1093/jnci/djs139

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  16 in total

1.  Do we need another selective estrogen receptor modulator for the adjuvant treatment of breast cancer?

Authors:  T Shenkier
Journal:  Curr Oncol       Date:  2013-08       Impact factor: 3.677

2.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Authors:  Hiltrud Brauch; Werner Schroth; Matthew P Goetz; Thomas E Mürdter; Stefan Winter; James N Ingle; Matthias Schwab; Michel Eichelbaum
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

3.  Breast cancer recurrence in relation to antidepressant use.

Authors:  Jessica Chubak; Erin J A Bowles; Onchee Yu; Diana S M Buist; Monica Fujii; Denise M Boudreau
Journal:  Cancer Causes Control       Date:  2015-10-30       Impact factor: 2.506

Review 4.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

5.  Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

Authors:  Stacie B Dusetzina; G Caleb Alexander; Rachel A Freedman; Haiden A Huskamp; Nancy L Keating
Journal:  Breast Cancer Res Treat       Date:  2012-11-13       Impact factor: 4.872

Review 6.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

Review 7.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

8.  Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

Authors:  Matthew P Goetz; James X Sun; Vera J Suman; Grace O Silva; Charles M Perou; Yusuke Nakamura; Nancy J Cox; Philip J Stephens; Vincent A Miller; Jeffrey S Ross; David Chen; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; Krishna R Kalari; Henry L Gomez; Ana M Gonzalez-Angulo; Octavio Burgues; Hiltrud B Brauch; James N Ingle; Mark J Ratain; Roman Yelensky
Journal:  J Natl Cancer Inst       Date:  2014-12-08       Impact factor: 13.506

Review 9.  Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.

Authors:  Geoffrey S Ginsburg; Nicole M Kuderer
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

Review 10.  Pharmacogenomics of breast cancer therapy: an update.

Authors:  Kelly Westbrook; Vered Stearns
Journal:  Pharmacol Ther       Date:  2013-03-13       Impact factor: 12.310
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.